As of Jul 22
| +0.045 / +7.14%|
The 1 analysts offering 12-month price forecasts for MabVax Therapeutics Holdings Inc have a median target of 2.50, with a high estimate of 2.50 and a low estimate of 2.50. The median estimate represents a +270.37% increase from the last price of 0.68.
The current consensus among 1 polled investment analysts is to Buy stock in MabVax Therapeutics Holdings Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.